The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cholesterol and prostate cancer
Open accessAbstract
Summary Prostate cancer risk can be modified by environmental factors, however the molecular mechanisms affecting susceptibility to this disease are not well understood. As a result of a series of recently published studies, the steroidal lipid, cholesterol, has emerged as a clinically relevant therapeutic target in prostate cancer. This review summarizes the findings from human studies as well as animal and cell biology models which suggest that high circulating cholesterol increases risk of aggressive prostate cancer, while cholesterol lowering strategies may confer protective benefit. Relevant molecular processes that have been experimentally tested and might explain these associations are described. We suggest that these promising results now could be applied prospectively to attempt to lower risk of prostate cancer in select populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model Systems, Lipid Rafts, and Cell Membranes
Simons, K., & Vaz, W. L. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.32.110601.141803 · Cited by 1,670
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Simons, K., & Ikonen, E. (2000) · Science · doi:10.1126/science.290.5497.1721 · Cited by 1,275
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567
Self-citationThe Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 528
Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea
Kitahara, C. M., Berrington de González, A., Freedman, N. D., Huxley, R., Mok, Y., Jee, S. H., & Samet, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5200 · Cited by 408
Statin Drugs and Risk of Advanced Prostate Cancer
Platz, E. A., Leitzmann, M. F., Visvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj499 · Cited by 406
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.
Zhuang, L., Lin, J., Lu, M. L., Solomon, K. R., & Freeman, M. R. (2002) · PubMed · Cited by 327
Self-citationCancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
Cholesterol and prostate cancer
Freeman, M. R., & Solomon, K. R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10724 · Cited by 266
Self-citationDillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Jacobs, E. J., Newton, C. C., Thun, M. J., & Gapstur, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2953 · Cited by 222
Pommier, A. J. C., Alves, G., Viennois, E., Bernard, S., Communal, Y., Sion, B., Marceau, G., Damon, C., Mouzat, K., Caira, F., et al. (2010) · Oncogene · doi:10.1038/onc.2010.30 · Cited by 206
Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study
Murtola, T. J., Tammela, T. L. J., Lahtela, J., & Auvinen, A. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0599 · Cited by 191
Leon, C. G., Locke, J. A., Adomat, H. H., Etinger, S. L., Twiddy, A. L., Neumann, R. D., Nelson, C. C., Guns, E. S., & Wasan, K. M. (2010) · The Prostate · doi:10.1002/pros.21072 · Cited by 168
The role of cholesterol in prostate cancer
Hager, M. H., Solomon, K. R., & Freeman, M. R. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232896.66791.62 · Cited by 154
Self-citationCholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort
Jacobs, E. J., Rodriguez, C., Bain, E. B., Wang, Y., Thun, M. J., & Calle, E. E. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0448 · Cited by 152
Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort
Flick, E. D., Habel, L. A., Chan, K. A., Eeden, S. K. V. D., Quinn, V. P., Haque, R., Orav, E. J., Seeger, J. D., Sadler, M. C., Quesenberry, C. P., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0197 · Cited by 152
Association between plasma cholesterol and prostate cancer in the PSA era
Platz, E. A., Clinton, S. K., & Giovannucci, E. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23715 · Cited by 140
Mostaghel, E. A., Solomon, K. R., Pelton, K., Freeman, M. R., & Montgomery, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030062 · Cited by 137
Self-citationCholesterol Sensitivity of Endogenous and Myristoylated Akt
Adam, R. M., Mukhopadhyay, N. K., Kim, J., Vizio, D. D., Cinar, B., Boucher, K., Solomon, K. R., & Freeman, M. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0288 · Cited by 134
Self-citationShafique, K., McLoone, P., Qureshi, K. N., Leung, H. Y., Hart, C., & Morrison, D. S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-25 · Cited by 130
HEART DISEASE RISK FACTORS, DIABETES, AND PROSTATIC CANCER IN AN ADULT COMMUNITY
THOMPSON, M. M., GARLAND, C., Barrett-Connor, E. L., et al. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115162 · Cited by 130
Do the cholesterol-lowering properties of statins affect cancer risk?
Solomon, K. R., & Freeman, M. R. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.12.004 · Cited by 125
Self-citationA Western-Type Diet Accelerates Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer
Llaverı́as, G., Danilo, C., Wang, Y., Witkiewicz, A. K., Daumer, K. M., Lisanti, M. P., & Frank, P. G. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100568 · Cited by 124
Ezetimibe Is an Inhibitor of Tumor Angiogenesis
Solomon, K. R., Pelton, K., Boucher, K., Joo, J., Tully, C., Zurakowski, D., Schaffner, C. P., Kim, J., & Freeman, M. R. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080551 · Cited by 117
Self-citationStatins and Prostate Cancer Diagnosis and Grade in a Veterans Population
Farwell, W. R., DʼAvolio, L., Scranton, R. E., Lawler, E. V., & Gaziano, J. M. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr108 · Cited by 106
Mondul, A. M., Clipp, S. L., Helzlsouer, K. J., & Platz, E. A. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9434-8 · Cited by 105
Hemelrijck, M. V., Garmo, H., Holmberg, L., Walldius, G., Jungner, I., Hammar, N., & Lambe, M. P. (2010) · Cancer · doi:10.1002/cncr.25758 · Cited by 103
Kollmeier, M. A., Katz, M. S., Mak, K. S., Yamada, Y. J., Feder, D. J., Zhang, Z., Jia, X., Shi, W., & Zeléfsky, M. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.006 · Cited by 92
The Complex Interplay Between Cholesterol and Prostate Malignancy
Solomon, K. R., & Freeman, M. R. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.04.001 · Cited by 88
Self-citationBatty, G. D., Mika Kivimaki, B., Clarke, R., Smith, G. D., & Shipley, M. J. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9691-6 · Cited by 80
Hemelrijck, M. V., Walldius, G., Jungner, I., Hammar, N., Garmo, H., Binda, E., Hayday, A., Lambe, M. P., & Holmberg, L. (2011) · Cancer Causes & Control · doi:10.1007/s10552-011-9774-z · Cited by 69
Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes
Freeman, M. R., Cinar, B., Kim, J., Mukhopadhyay, N. K., Vizio, D. D., Adam, R. M., & Solomon, K. R. (2006) · Steroids · doi:10.1016/j.steroids.2006.11.012 · Cited by 68
Self-citationBlood lipid levels and prostate cancer risk; a cohort study
Kok, D. E. G., van Roermund, J. G. H., Aben, K. K. H., den Heijer, M., Swinkels, D. W., Kampman, E., & Kiemeney, L. A. L. M. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.30 · Cited by 68
Statins increase the risk of prostate cancer: A population‐based case–control study
Chang, C., Ho, S., Chiu, H., & Yang, C. (2011) · The Prostate · doi:10.1002/pros.21401 · Cited by 58
Cholesterol and benign prostate disease
Freeman, M. R., & Solomon, K. R. (2011) · Differentiation · doi:10.1016/j.diff.2011.04.005 · Cited by 56
Self-citationMondul, A. M., Han, M., Humphreys, E. B., Meinhold, C. L., Walsh, P. C., & Platz, E. A. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.11.089 · Cited by 53
The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based Cohort
Breau, R. H., Karnes, R. J., Jacobson, D. J., McGree, M. E., Jacobsen, S. J., Nehra, A. X., Lieber, M. M., & Sauver, J. L. S. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.03.149 · Cited by 51
Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy
Tan, N., Klein, E. A., Li, J., Moussa, A. S., & Jones, J. S. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.03.004 · Cited by 48
Effect of statin use on biochemical outcome following radical prostatectomy
Ritch, C. R., Hruby, G. W., Badani, K. K., Benson, M. C., & McKiernan, J. M. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10159.x · Cited by 37
Fowke, J. H., Motley, S. S., Barocas, D. A., Cookson, M. S., Concepcion, R. S., Byerly, S. H., & Smith, J. A. J. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9713-4 · Cited by 27
Huxley, R., Ansary-Mohaddam, A., Huxley, R., Barzi, F., Lam, T. H., Jamrozik, K. D., Ohkubo, T., Fang, X., Sun, H. J., Woodward, M., et al. (2007) · PubMed · Cited by 27
Prohibitin is a cholesterol‐sensitive regulator of cell cycle transit
Dong, P., Flores, J., Pelton, K., & Solomon, K. R. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22865 · Cited by 25
Self-citationStatins and the Risk of Cancer
Freeman, M. R., Solomon, K. R., & Moyad, M. A. (2006) · JAMA · doi:10.1001/jama.295.23.2720-b · Cited by 19
Self-citationEffect of Statins and Anticoagulants on Prostate Cancer Aggressiveness
Alizadeh, M., Sylvestre, M., Zilli, T., Nguyen, T. V., Guay, J.-P., Bahary, J.-P., & Taussky, D. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.042 · Cited by 16
Cited by
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
The Role of Cholesterol in Cancer
Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2613 · Cited by 708
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421601112 · Cited by 454
Metadata
- Authors
- Pelton, K., Freeman, M. R., & Solomon, K. R.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 12
- Issue
- 6
- Pages
- 751-759
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2014393189
- Cited by
- 303
- References
- 47
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.